Xencor (XNCR) Cash from Investing Activities Growth (1y) (2014 - 2026)
Powered by 
Analysis
Xencor (XNCR) Cash from Investing Activities Growth (1y) (2014 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | 90.55% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 91.53% |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | -41.67% |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | 25.90% |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | -157.08% |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | 26.37% |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | -89.24% |
| 10 | Xencor | 2.02 Bn | 1.64 Bn | - | 110.30% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 110.30% |
| Mar 31, 2026 | 95.18% |
| Dec 31, 2025 | 24.32% |
| Sep 30, 2025 | 108.97% |
| Jun 30, 2025 | -38.69% |
| Mar 31, 2025 | -57.71% |
| Dec 31, 2024 | 128.18% |
| Sep 30, 2024 | -460.63% |
| Jun 30, 2024 | 4,798.65% |
| Mar 31, 2024 | -32.87% |
| Dec 31, 2023 | -927.48% |
| Sep 30, 2023 | 1,350.43% |
| Jun 30, 2023 | 98.14% |
| Mar 31, 2023 | 167.09% |
| Dec 31, 2022 | 212.32% |
| Sep 30, 2022 | 108.04% |
| Jun 30, 2022 | -41.89% |
| Mar 31, 2022 | -288.60% |
| Dec 31, 2021 | -90.02% |
| Sep 30, 2021 | 23.16% |